Introduction {#Sec1}
============

Gene expression profiling (GEP) via DNA microarrays has been used extensively in cancer research to study disease mechanisms and make predictions of clinical outcomes. A typical microarray data analysis focuses on the selection of individual genes. For example, to identify differentially expressed genes under different conditions, one typically calculates a statistic and p value for each gene, followed by multiple comparison adjustments since normally tens of thousands of genes are measured in a microarray experiment. To select genes for predicting clinical outcomes, one can resort to methods such as semi-supervised principal component analysis (SuperPC) \[[@CR1]\], partial least squares \[[@CR2]\], Lasso \[[@CR3]\], random forest \[[@CR4]\], and so on. However, this type of analysis can miss some important genes whose individual contributions to a particular outcome may be moderate but whose combined effects are significant. Another limitation of the individual-gene approach is frequently inconsistent gene findings from similar studies conducted by different institutes \[[@CR5], [@CR6]\]. These problems of the individual-gene analysis were discussed in Mootha et al. \[[@CR7]\] and Subramanian et al. \[[@CR8]\], where they proposed a gene set enrichment analysis (GSEA) idea, incorporatingprior biological knowledge into the analysis routine to identify important genes through gene sets. Since then many new statistical methods have been proposed for making inference on associations or predictions at gene set levels instead of individual-gene levels.

A gene set is a group of genes related in certain ways (e.g., they may be from the same pathway or perform similar molecular functions). There are public databases holding such information, for example those with the Gene Ontology (GO) annotations \[[@CR9]\] and the Kyoto Encyclopedia of Genes and Genomes ( KEGG) pathways \[[@CR10]\]. For differential expression analysis, a gene set method aims to determine via hypothesis testing whether a gene set as a whole is associated with an outcome of interest. Examples include the pioneering GSEA algorithm \[[@CR8]\], the Global Test \[[@CR11]\], ANCOVA Global Test \[[@CR12]\], SAM-GS \[[@CR13]\], and GSA \[[@CR14]\], to name just a few. For biomarker discovery, i.e. finding genes to build models for diagnostic/prognostic purposes, the idea of incorporating gene set information is to improve both performance and interpretability of resulting models. Tai and Pan \[[@CR15]\] proposed a modified linear discriminant analysis (LDA) approach for classification by regularizing the covariance matrix and incorporating correlations among the genes within gene sets. With simulated and real datasets plus information from KEGG pathways, they showed that the new approach performed better than not incorporating the correlations within gene sets. Chen and Wang \[[@CR16]\] proposed a two-step procedure: first to create a "super gene score" using SuperPC \[[@CR1]\] within each a priori gene set obtained from GO and then to use Lasso or SuperPC again to build a final model based on the super gene scores. With two survival microarray data they demonstrated that their gene set-based models enjoyed improved prediction accuracy and generated more biologically interpretable results. Ma et al. \[[@CR17]\] also took a two-step approach, where they first divided genes into clusters by k-means, followed by applying Lasso within each cluster to get refined gene clusters, and then they selected important gene clusters with group Lasso \[[@CR18]\]. Luan and Li \[[@CR19]\] proposed a group additive regression model to incorporatepathway information and the use of gradient descent boosting for model fitting. With both simulations and a real microarray survival dataset, they showed improved accuracy by their method when compared to not using gene group information.

In this paper, we aim to investigate several score methods in conjunction with trees and random forests for gene set analysis and compare with individual-gene analysis in classification problems. In the individual-gene analysis, neither the gene selection nor theprediction process utilizes any biological information. For the gene set analysis, we first identify important genes within a priori gene sets to create summary gene set scores, and we then use the gene set scores as predictors for constructing predictive models. We explore four myeloma microarray datasets and three types of gene sets, and demonstrate that predictive accuracy depends on both the method and the type of gene sets being investigated. In the next section we first introduce our datasets from myeloma research. We then describe the analysis methods in Sect. [3](#Sec3){ref-type="sec"} and show our results from applying the methods to the myeloma datasets in Sect. [4](#Sec9){ref-type="sec"}. Finally in Sect. [5](#Sec15){ref-type="sec"}, we conclude with a comparison of our results with findings reported by others.

Datasets {#Sec2}
========

All GEP datasets used in this investigation were from the Myeloma Institute (MI) at the University of Arkansas for Medical Sciences (UAMS). Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow, with symptoms such as elevated **c**alcium, **r**enal failure, **a**nemia, and **b**one lesions (the so-called CRAB symptoms). Normal plasma cells produce many immunoglobulins (antibodies) that the body needs to identify and fight pathogens such as bacteria and viruses. With MM, abnormal plasma cells from a single clone accumulate and eventually crowd out normal plasma cells, causing the body to produce only one type of immunoglobulin. It is not clear what causes MM, but it is characterized by genetic abnormalities such as gene mutations and translocations. For example, deletions of chromosome 17p and *P53* gene mutations have been linked to poor clinical outcomes in numerous MM studies. Typically prior to developing MM, abnormal plasma cells accumulate in the body and the patient undergoes an asymptomatic phase, comprising monoclonal gammopathy of uncertain significance (MGUS) and smoldering multiple myeloma (SMM). Compared to MGUS, SMM has more abnormal plasma cells in the bone marrow and higher levels of monoclonal immunoglobulin (M-protein) in the serum. Both MGUS and SMM patients lack the CRAB symptoms that define MM. However, MGUS patients have an approximately 1% risk per year of developing MM \[[@CR20]\]. Among patients with SMM, about 10% annually will progress to MM within 5 years, and after the 5-year mark the progression rate is similar to MGUS \[[@CR21]\].

In previous work, based on an earlier Affymetrix platform with \~12,000 genes, we identified differentially expressed genes that could distinguish in plasma cells between normal and MM and between normal and MGUS \[[@CR22]\]. An interesting finding at the time was a lack of ability of the models to discriminate between MGUS and MM at the gene expression level. Based on the newer platform U133Plus2, and more samples, we aimed to do a more refined analysis in this investigation, specifically to identify signature genes and build predictive models to distinguish between (1) normal and MGUS, (2) MGUS and SMM, (3) SMM and MM, and (4) *P53* deletion and no deletion in MM. The MM patients in this study were enrolled in a series of Total Therapy (TT) clinical trials, with the MGUS/SMM patients in two observational clinical trials (SWOG S0120 and MI M0120). *P53* deletion was determined at baseline by interphase fluorescence in situ hybridization (iFISH). For GEP, purified plasma cells (PC) by CD138 expression were obtained from normal healthy subjects and the MM (MGUS/SMM) patientsprior to therapy (at registration of the observational trials). Microarray raw intensity values were preprocessed and normalized using the MAS5 algorithm provided by the manufacturer, and the normalized data also went through batch effect checking and corrections \[[@CR23]\].

Methods {#Sec3}
=======

Table [1](#Tab1){ref-type="table"} gives the sample sizes in each dataset. To ensure data quality, we first implemented the following steps prior to analysis:Use the genes with current annotations from Affymetrix.Take the median if a gene is represented by more than one probe set.Keep only those genes whose raw intensity values are \>128 in at least 80% of the samples to avoid any resolution problems that may be encountered by low microarray intensity values.Since applying the above procedure to each GEP dataset separately produced similar sets of genes, for simplicity we applied it to all the data combined to obtain a total of 9624 genes before analysis.Table 1Number of samples used in the training and test sets for each disease comparisonDisease comparisonGroup 0Group 1\# samples in training set (group 0, group 1)\# samples in test set (group 0, group 1)Normal versus MGUSNormalMGUS(25, 73)(13, 44)MGUS versus SMMMGUSSMM(73, 89)(44, 75)SMM versus MMSMMMM(89, 174)(74, 178)*P53* deletion versus no deletionwithout *P53* deletionwith *P53* deletion(377, 45)(294, 29)

What Gene Sets to Use? {#Sec4}
----------------------

There are different types and sources of biological gene sets. The Molecular Signatures Database (MSigDB) \[[@CR24]\] on the Broad Institute website is one of the largest and most popular repositories. We downloaded three types of gene sets from MSigDB: those associated with the GO biological processes (BP), the hallmark gene sets, and the positional gene sets. Each gene set groups certain genes together that share a particular biological property. GO BP gene sets contain genes associated with biological processes, each of which is made up of many chemical reactions or events leading to chemical transformations. However, the GO BP gene sets are a broad category and do not necessarily comprise co-regulated genes. On the other hand, the hallmark gene sets represent well-defined biological states or processes and contain genes with coordinate expression \[[@CR25]\]. The positional gene sets group genes by chromosome and cytogenetic band. Such gene sets are helpful in identifying effects related to chromosome abnormalities.

Approach for Gene Set Analysis {#Sec5}
------------------------------

Our general approach for gene set analysis is a two-step procedure: (1) within each a priori gene set create a summary gene set score after gene selection, and (2) construct a predictive model based on the resulting gene set scores. Both Chen and Wang \[[@CR16]\] and Ma et al. \[[@CR17]\] pointed out that typically not all members of a gene set will participate in a biological process, or be relevant to the outcome of interest, and not doing gene selection within gene sets could result in inferior prediction accuracy. Thus we carry out variable selection twice, first to select important genes within each gene set to calculate a summary gene set score (step 1), and then to select important gene sets based on the gene set scores and build a final predictive model (step 2).

Variable Selection and Model Building {#Sec6}
-------------------------------------

We investigated several linear and nonlinear methods for variable selection and model building. The linear methods included the Lasso and three univariate score methods, and the nonlinear methods included decision trees and random forests.
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There is a rich literature concerning the development of predictive models using decision trees and random forests and their applications in genomic data analysis (e.g., see \[[@CR4], [@CR30]--[@CR34]\]). A decision tree model based on recursive partitioning has the advantage of easy interpretation. In a random forest model, many decision trees are built by utilizing bootstrap samples and results from each tree are aggregated by majority voting to make final predictions. By building each tree to the fullest, the method is able to achieve low bias, and by aggregating results from many trees it can also achieve low variance. Importantly, a random forest considers only a random subset of the variables at each split. Doing so allows it to (1) produce less similar bootstrap samples and trees and therefore low variance at the end, and (2) identify a diverse set of important variables associated with the outcome of interest even when there is multicollinearity in the data. We implemented decision trees and random forests via the R packages *rpart* and *randomForest*.

For the individual-gene analysis, we used methods such as the Lasso, score, ccscore, pcscore, trees, and random forests. For the gene set analysis, to maintain focus we considered only various (instead of all) combinations of the methods from individual-gene analysis. As genes within a biological gene set are more likely to be co-regulated or co-expressed, we restricted to linear methods in step 1 (within gene sets), while in step 2 (between gene sets) we explored both linear and nonlinear methods. There were a total of 15 combinations in the gene set analysis we considered. We denote each combined methodology by using a period between the names of the methods used in the two steps. For example, suppose in step 1 we chose the score method to select genes while in step 2 trees were employed; we would refer to the combined method by score.tree. Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} list all the methods and their notations for both the gene set and individual-gene analysis.Table 2Methods investigated in individual-gene analysisClassification methodNotationLassoLassoscorescoreccscoreccscorepcscorepcscoredecision treetreerandom forestrf Table 3Methods investigated in gene set analysisClassification method (within gene sets + between gene sets)NotationLasso + Lassolasso.lassoLasso + random forestlasso.rfLasso + treelasso.treescore + Lassoscore.lassoscore + scorescore.scorescore + random forestscore.rfscore + treescore.treepcscore + Lassopcscore.lassopcscore + pcscorepcscore.scorepcscore + random forestpcscore.rfpcscore + treepcscore.treeccscore + Lassoccscore.lassoccscore + ccscoreccscore.ccscoreccscore + random forestccscore.rfccscore + treeccscore.tree

Cross-Validation to Determine Tuning Parameter {#Sec7}
----------------------------------------------

For the univariate score methods described above, we employed 10-fold cross-validation to select appropriate values for the tuning parameter $\documentclass[12pt]{minimal}
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                \begin{document}$$ max_{i} \text{(}\left| {t_{i} } \right|\text{)} $$\end{document}$ as suggested in ([1](#Equ1){ref-type=""}--[3](#Equ3){ref-type=""}), which can be a big range. To reduce computational burden, we restricted our search within the range of 1000 most significant genes when doing the cross-validation. For example, if the absolute values of the t statistic in the top 1000 genes vary between 4.5 and 5.6, we would assess each value from 4.5 to 5.6, with an increment of 0.1 in search of an optimal threshold for $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \Delta $$\end{document}$. We used error rate as the performance measure in the cross-validation.

Model Comparison {#Sec8}
----------------

Each of the four datasets was split into training and test sets (Table [1](#Tab1){ref-type="table"}), and we only report error rates from the test sets as a guide to compare performance of the different methods. All model building steps were performed in the training sets, including gene selection or shrinkage parameter estimation with cross-validation.

Results {#Sec9}
=======

There are currently a total of 825 GO BP, 50 hallmark, and 326 positional gene sets on the Broad website that we downloaded. Due to the fact that we had previously performed a gene filtering step, we were left with fewer numbers of gene sets (736 GO BP, 50 hallmark, and 278 positional) as well as fewer genes within the gene sets when we applied these gene sets to our datasets. We also focused on gene sets containing at least 5 genes. Table [4](#Tab4){ref-type="table"} gives a summary of the number of genes in the gene sets of our datasets. Both the GO BP and positional categories have a small percent of gene sets with a large number of genes in them. However, if we look at the median number of genes within gene sets, the hallmark gene sets have the largest number (86) followed by the GO BP gene sets (54.76) and the positional gene sets (25.9).Table 4Summary on number of genes within each type of gene sets in our datasetsType of gene setsMinimum1st. quartileMedianMean3rd. quartileMaximumGO BP591654.76471110Hallmark950.585.586114186Positional5101725.930281

Methods Comparison {#Sec10}
------------------

Table [5](#Tab5){ref-type="table"} shows the test set error rates achieved in the individual-gene analysis for each disease comparison. To compare the methods, we ranked them by their averaged error rates (AER) over all the disease comparisons---lower AER is better. Overall, ccscore and score ranked as the top two classifiers in the individual-gene analysis with AER being 0.16 and 0.17 respectively, followed by Lasso (AER = 0.19), random forest (AER = 0.20), and pcscore (AER = 0.20), and the tree method ranked the lowest (AER = 0.22). Note that the AER were rounded to the 2nd decimal point while the rankings were calculated using all decimal points.Table 5Test set error rates achieved in the individual-gene analysis (columns 2--5), where D1, D2, D3, D4 denote the four disease comparisons: normal versus MGUS, MGUS versus SMM, SMM versus MM, p53 deletion versus no deletion, respectivelyClassification methodD1D2D3D4AverageRank by averageccscore0.160.310.100.100.161score0.190.310.080.100.172lasso0.250.390.060.070.193rf0.230.360.120.090.204pcscore0.190.310.150.160.205tree0.280.320.190.100.226The last two columns have the averaged error rates (average) over 4 disease comparisons and the rankings of the methods by the averaged error rates

For the gene set methods, Table [6](#Tab6){ref-type="table"} gives the test set error rates for each disease comparison/type of gene sets combination (a total of 12 scenarios). Note that both the method and type of gene sets affected the error rates for each disease comparison. We ranked the methods by their averaged error rates (AER) across all 12 scenarios. It turned out that lasso. lasso and all the methods that employed trees in step 2 of the gene set analysis were low performers. However, Lasso performed well in conjunction with random forests. When not combined with trees in the 2nd step, the ccscore-related methods consistently ranked at the top followed by the pcscore- and score-related methods, although the differences among them were small (≤0.02) by the AER measure. More often than not, random forests were good choices when combined with the score methods or Lasso.Table 6Test set error rates achieved in the gene set analysis using 3 types of gene sets (GO BP, hallmark, and positional), where D1, D2, D3, D4 denote the four disease comparisons: normal versus MGUS, MGUS versus SMM, SMM versus MM, p53 deletion versus no deletion, respectivelyClassificationGO BPHallmarkPositionalAverageRank by averageMethodD1D2D3D4D1D2D3D4D1D2D3D4ccscore.ccscore0.180.370.060.090.210.300.090.080.180.320.080.070.172ccscore.lasso0.180.370.060.090.210.300.090.080.180.320.080.070.172ccscore.rf0.180.350.110.090.180.300.090.070.140.310.100.070.161ccscore.tree0.140.310.140.080.230.350.140.070.260.350.130.080.1911score.score0.210.350.070.090.210.310.090.090.210.320.100.070.189score.lasso0.210.350.070.090.210.310.090.090.210.320.100.070.189score.rf0.190.320.120.100.180.300.100.070.160.330.120.060.177score.tree0.230.350.120.090.320.350.150.080.180.380.170.080.2114pcscore.pcscore0.210.360.080.090.190.300.100.080.160.310.090.080.174pcscore.lasso0.210.360.080.090.190.300.100.080.160.310.090.080.174pcscore.rf0.210.350.110.090.180.310.120.070.120.310.130.070.178pcscore.tree0.230.370.150.090.260.360.150.090.210.390.140.090.2115lasso.lasso0.210.370.050.090.260.350.060.100.250.430.100.100.2012lasso.rf0.160.370.060.080.140.330.050.090.190.420.060.090.176lasso.tree0.260.370.060.100.180.440.060.100.190.500.090.080.2013The last two columns have the averaged error rates (average) over all disease comparisons/types of gene sets and the rankings by the averaged error rates

Gene Set Analysis Versus Individual-Gene Analysis {#Sec11}
-------------------------------------------------

The question is: did the gene set analysis improve prediction accuracy over the individual-gene analysis? We compared the two types of analysis by calculating differences in error rates. For example, suppose in individual-gene analysis we used the Lasso, then we would compare it with those gene set methods that employed Lasso in 2nd step of the gene set analysis such as ccscore.lasso, score.lasso, pcscore.lasso, and lasso.lasso. By doing such comparisons, one can gauge whether step 1 of the gene set analysis is necessary---without step 1 the gene set analysis just reduces to individual-gene analysis. Table [7](#Tab7){ref-type="table"} lists reductions in error rate by using gene set analysis compared to individual-gene analysis in all such comparisons. Note that each gene set method was applied for each disease comparison three times, each time utilizing a different kind of gene sets (either GO BP, hallmark, or positional), while each individual-gene method was applied only once for each disease comparison. Thus when calculating the differences in error rate, we replicated those error rates of the individual-gene methods three times. We can see in Table [7](#Tab7){ref-type="table"} that both the method and the type of gene sets affected whether there was any improvement in performance by doing gene set analysis, where improvement was measured by reduction in error rate. We highlighted those scenarios when the reductions in error rate by doing gene set analysis were somewhat meaningful (≥0.04), although 0.04 is an arbitrary choice. The fact that there are both positive and negative values in Table [7](#Tab7){ref-type="table"} indicates that sometimes individual-gene analysis was better than gene set analysis in terms of prediction accuracy. Averaged reductions in error rate were also calculated for each gene set method in comparison to an appropriate individual-gene method (last column of Table [7](#Tab7){ref-type="table"}). By this measure, all 15 gene set methods except two produced more accurate models with reduced error rates. Figure [1](#Fig1){ref-type="fig"} provides a visualization of the reductions in error rate. Despite the variations, overall across all the methods, gene set analysis reduced error rates by 0.02 on average, and 25% of the time by at least 0.05.Table 7Reductions in test set error rate by doing gene set analysis compared to individual-gene analysis, where D1, D2, D3, D4 denote the four disease comparisons: normal versus MGUS, MGUS versus SMM, SMM versus MM, p53 deletion versus no deletion, respectivelyGene set analysis methodIndividual gene analysis methodGO BPHallmarkPositionalAverageD1D2D3D4D1D2D3D4D1D2D3D4ccscore.ccscoreccscore−0.02−0.07**0.04**0.01−0.050.010.010.01−0.02−0.020.020.030.00score.scorescore−0.02−0.040.010.01−0.02−0.01−0.010.01−0.02−0.02−0.020.03−0.01pcscore.pcscorepcscore−0.02−0.05**0.080.08**00.01**0.060.080.04**−0.01**0.060.09**0.03ccscore.lassolasso**0.07**0.020−0.02**0.040.09**−0.02−0.02**0.070.07**−0.0200.02score.lassolasso**0.040.04**−0.01−0.02**0.040.08**−0.03−0.02**0.040.07**−0.0400.01pcscore.lassolasso**0.04**0.03−0.01−0.02**0.050.09**−0.03−0.02**0.090.08**−0.03−0.010.02lasso.lassolasso**0.04**0.020.01−0.02−0.02**0.04**0−0.030−0.04−0.04−0.03−0.01ccscore.rfrf**0.05**0.010.010.01**0.050.06**0.030.02**0.090.04**0.020.020.03score.rfrf**0.04**0.0300**0.050.06**0.020.02**0.07**0.0300.030.03pcscore.rfrf0.020.010.010.01**0.050.05**00.02**0.110.04**−0.010.020.03lasso.rfrf**0.07**−0.02**0.06**0.02**0.09**0.03**0.07**0**0.04**−0.06**0.06**00.03ccscore.treetree**0.14**0.02**0.04**0.01**0.05**−0.03**0.05**0.020.02−0.03**0.06**0.020.03score.treetree**0.05**−0.03**0.06**0−0.04−0.030.030.02**0.11**−0.060.010.010.01pcscore.treetree**0.05**−0.050.030.010.02−0.030.030.01**0.07**−0.07**0.04**0.010.01lasso.treetree0.02−0.05**0.13**0**0.11**−0.12**0.13**0**0.09**−0.18**0.1**0.020.02Values that are ≥0.04 are bold-faced. The last column (average) gives the averaged reductions in error rate Fig. 1Boxplots of the reductions in test set error rate (shown in Table [7](#Tab7){ref-type="table"}) by using each of 15 gene set methods compared to corresponding individual-gene methods

Disease Comparisons {#Sec12}
-------------------

Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"} is also a good summary of the overallprediction error rates for the disease comparisons. To have a focused discussion here, we consider only the ccscore and ccscore. lasso methods in this subsection and the next, as respectively they were among the top methods used in the individual-gene and gene set analysis. It appears that both the individual-gene and gene set methods were able to classify SMM versus MM and *P53* deletion versus no deletion very well with error rates varying between 0.06 and 0.10. Clinically, SMM is characterized by a higher percentage of abnormal plasma cells in the bone marrow and higher levels of M-protein in the serum than MGUS. Thus being able to classify SMM versus MM implies being able to discriminate between MGUS and MM as well. It turned out that our hypothesis was right when we went to verify it---the test set error rate for discriminating between MGUS and MM by an individual-gene analysis with the ccscore was 0.099. This is contradictory to the findings reported in Hardin et al. \[[@CR22]\], where all the models failed to classify MGUS versus MM. A couple of factors could be the cause here. First, the newer microarray platform U133Plus2 covers the whole genome more comprehensively than the older platform, so there is a better chance to detect differentiable genes and therefore create more powerful models. Second, we had more MGUS samples in this investigation: 73 compared to 21 in Hardin et al. \[[@CR22]\], while the MM samples in both investigations were plenty (174 in ours and 218 in Hardin et al.). Nonetheless, the difficult case for us was to discriminate between MGUS and SMM, as the error rates for this classification were between 0.3 and 0.37 for the individual-gene and gene set analysis. This indicates that at the molecular level MGUS and SMM are different for the most part, yet they share certain genetic features that make them less indistinguishable. Also interesting were the error rates for classifying MGUS versus normal varied between 0.16 and 0.21.

Taken together, these data seem to suggest that in terms of gene expression levels SMM is very different from MM, while MGUS is somewhere between normal and SMM, but more similar to SMM. At this point careful interpretation of the results is warranted. When using CD138 expression to isolate plasma cells (PC) before GEP---a standard procedure routinely performed at the Myeloma Institute, the MGUS/SMM PC samples were infiltrated with normal PC, while the MM PC samples were largely abnormal. Consequently, some of the differentially expressed genes we identified between MGUS/SMM PC and MM PC samples might be due to differences in the amount of normal PC in the samples rather than due to disease differences. This problem was less when comparing normal versus MGUS and MGUS versus SMM PC samples, as they were more comparable in terms of the amount of normal PC in the samples.

Gene Lists and Gene Selection {#Sec13}
-----------------------------

We provide a list of genes and gene sets identified for each disease comparison by the ccscore and ccsore.lasso methods from the individual-gene and gene set analysis respectively (for the same reason described in the last subsection) (Tables [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"}, [10](#Tab10){ref-type="table"}, and [11](#Tab11){ref-type="table"}). For the ccscore. lasso gene set analysis, we chose the gene set that gave the best result for each disease comparison (2nd row in Table [6](#Tab6){ref-type="table"}). Furthermore, we summarized the total number of genes identified by the two types of analysis. In all except the comparison of *P53* deletion versus no deletion, more genes were selected by ccscore.lasso than ccscore, with comparatively few overlapping genes (Table [12](#Tab12){ref-type="table"}).Table 8Genes and gene sets identified from the classification of normal versus MGUS (the methods used were ccscore and ccscore.lasso for the individual-gene and gene set analysis, respectively)Disease comparisonAnalysis typeGene setGenesNormal versus MGUSIndividual-gene analysis*AMPD3, APOBEC3B, ARPC5L, ATP6V0E1, CCDC6, CD81, CDKN1A, DHX29, EFHC1, HACD2, HCST, HGF, MOB3B, NDNF, PASK, RTN4, TMEM167A, TMEM38B, TMX1, TPST2*Gene set analysis (GO BP)POSITIVE REGULATION OF RESPONSE TO STIMULUS*UBE2* *N*REGULATION OF SECRETION*PYCARD, DNAJC1*SYSTEM DEVELOPMENT*RTN4, UGT8*BIOGENIC AMINE METABOLIC PROCESS*OAZ2*REGULATION OF BIOLOGICAL QUALITY*CDKN1A, CDKN2C, HIF1A, CD59, GLRX2, UBB, NDUFS1, CLCN3*DNA METABOLIC PROCESS*POLD1, POLE, UBE2* *N, GADD45A, CDK2AP1, MMS19, RAD51C, ERCC1, IGF1, DNMT3B, UBE2B, RBMS1, CDC6*BIOPOLYMER CATABOLIC PROCESS*UBE2* *N, ERCC1, UBE2B, UBE4A, UBB, GSPT1, UPF2, AMFR, ANAPC4*RNA METABOLIC PROCESS*ESRRG, TCF7, RBFOX2, HIF1A, NR1D2, TROVE2, SOD2, MMS19, RBPJ, MDFIC, RSF1, TCF19, CEBPB, SUPT16H, NR3C1, POU2F2, SMARCA2, TFDP1, HNRNPC, RBMS1, GSPT1, NMI, UPF2*PROTEIN OLIGOMERIZATION*STOM, DGKD*DNA REPAIR*POLD1, POLE, UBE2* *N, GADD45A, MMS19, RAD51C, ERCC1, UBE2B*POSITIVE REGULATION OF TRANSLATION*SPN*MUSCLE DEVELOPMENT*TAZ, IGF1, UBB*POSITIVE REGULATION OF CELL DIFFERENTIATION*SOCS5*PROTEIN FOLDING*FKBP5, GLRX2*PHOSPHOLIPID BIOSYNTHETIC PROCESS*CD81*NEGATIVE REGULATION OF NUCLEOBASENUCLEOSIDENUCLEOTIDE AND NUCLEIC ACID METABOLIC PROCESS*RBFOX2, RBPJ, RSF1*GLYCEROPHOSPHOLIPID BIOSYNTHETIC PROCESS*CD81, PIGC*NUCLEOBASENUCLEOSIDE AND NUCLEOTIDE METABOLIC PROCESS*AMPD3, NDUFS1, DCTD, FIGNL1*NEGATIVE REGULATION OF CELLULAR METABOLIC PROCESS*CDKN1A, RBFOX2, CDKN2C, RBPJ, RSF1, ERCC1, SIGIRR, CDC6, DNAJC1*PROTEIN AUTOPROCESSING*KIAA1804* Table 9Genes and gene sets identified from the classification of MGUS versus SMM (the methods used were ccscore and ccscore.lasso for the individual-gene and gene set analysis, respectively)Disease comparisonAnalysis typeGene setGenesMGUS versus SMMIndividual-gene analysis*CTSH, GATA2, GSTA1, IGHD, IGHM, IGK, IGKC, IGLC1, IGLJ3, IGLV1*-*44, TNFRSF18*Gene set analysis (Hallmark)TNFA SIGNALING VIA NFKB*BIRC3, TNIP1, ID2, NFAT5, TNFAIP3*DNA REPAIR*SUPT5H, AAAS, POLE4*APOPTOSIS*IGFBP6, BIRC3, CYLD*PROTEIN SECRETION*SEC31A, RAB2A*INTERFERON GAMMA RESPONSE*HIF1A, IL10RA, TNFAIP3*COMPLEMENT*CTSH, CALM1, TNFAIP3, APOBEC3F, PLA2G4A*EPITHELIAL MESENCHYMAL TRANSITION*EFEMP2*IL2 STAT5 SIGNALING*TNFRSF18, CD81, IL10RA, CDC42SE2* Table 10Genes and gene sets identified from the classification of SMM versus MM (the methods used were ccscore and ccscore.lasso for the individual-gene and gene set analysis, respectively)Disease comparisonAnalysis typeGene setGenesSMM versus MMIndividual-gene analysis*ATXN7L3B, C2CD4C, CDC5L, CDT1, DENND2D, FOXO1, GMIP, KIAA1033, KLHDC3, MELK, MTUS1, NCOA1, ND6, RPL37A, RPL38, RRM2, SH3KBP1, STIL, ZWINT*Gene set analysis (GO BP)POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS*GLMN, AKTIP, ANG, IL20, LYN*NEGATIVE REGULATION OF CELLULAR METABOLIC PROCESS*CDT1, ZHX1, GMNN, DRAP1, TIPIN, ZMYND11, PA2G4, GTPBP4, PHB, STAT3*REGULATION OF HYDROLASE ACTIVITY*CASP9, ADAP1, MTCH1, ANG, CDKN2A, FGD2, S1PR4*TRNA PROCESSING*ADAT1, AARS, SARS*REGULATION OF BIOLOGICAL QUALITY*LMAN1, GTPBP4, SLC40A1, GCHFR, ACVR2A, CXCL12, CD59, XRN2, CDKN2C, EIF2B2, EIF2B5, PAIP1, ERP44, SOD1, CALR, BDKRB1, FXN, F7, GPI, CAPRIN2, BARD1, NPC2, NDUFS1, TARBP2, CDKN2A, NOTCH2, CLCN3, FTH1, LYN, FLI1, SLC30A5, CYSLTR1, CDKN1A, FGD2, SERTAD2, AGT, NPTN, CLN3, APTX, DERL2, COG3, NEBL, S1PR4, GCLM, ENO1, SMAD4, LDB1, ARF6, CCDC88C, WAS, CEBPG, RPS19, CAPG, SGMS1*DNA METABOLIC PROCESS*CDT1, PURA, RBBP8, KPNA2, GMNN, POLE3, TIPIN, ATRX, TLK1, CHEK1, GTPBP4, XAB2, FEN1, IGF1, MCM2, PARP3, TINF2, SUPV3L1*AMINO SUGAR METABOLIC PROCESS*CSGALNACT1, NAGK*BIOPOLYMER CATABOLIC PROCESS*UBE2C, ANAPC2, GSPT1, AMFR, STUB1, UBE2G1, UBE2H, ABCE1, FBXO22, XRN2, RNASEH2A, SOD1, ANAPC10, UBE2E1, HNRNPD, CDC23, PSMD14, CDKN2A*RNA METABOLIC PROCESS*FOXO1, PTTG1, ZHX1, TRIP13, EZH2, RBBP8, KLF7, DRAP1, ZNF367, ZMYND11, ASH1L, PA2G4, ATRX, RUVBL1*PROTEIN POLYUBIQUITINATION*AMFR, STUB1*PROTEIN OLIGOMERIZATION*STOM, AMFR, TRPV5, INSR, NOD1, DGKD, CCDC88C, MALT1*DNA REPAIR*RBBP8, ATRX, XAB2, FEN1, PARP3, POLD1, RUVBL2, RAD23B, MSH3, SOD1, MMS19, CSNK1D*POSITIVE REGULATION OF TRANSLATION*SPN, TLR1, TNFRSF8, GLMN, EIF2B5, TLR6*RESPONSE TO VIRUS*CXCL12, APOBEC3F, ABCE1, RSAD2, BNIP3L, IFNAR1, IFNGR1, TARBP2, IFNAR2, APOBEC3G*MUSCLE DEVELOPMENT*UTRN, IGF1, NOTCH1, SOD1, FKTN, MYBPC3*POSITIVE REGULATION OF CELL DIFFERENTIATION*ACVR2A, SOCS5, IL20, BOC, BTG1*MITOTIC CELL CYCLE CHECKPOINT*ZWINT, CCNA2, BUB1B, MAD2L1, PCBP4*ACTIN FILAMENT ORGANIZATION*KPTN, SORBS3, ARHGEF10L, SHROOM2, NF2*PROTEIN FOLDING*LMAN1, CCT4, HSPE1, PFDN4, STUB1, ERP29, RUVBL2, CCT3, DNAJB2, ERP44, CCT6A, PPIH, DNAJA1, CLN3, UGGT1, PPIA, FKBP5, CLPX*REGULATION OF RHO PROTEIN SIGNAL TRANSDUCTION*RAC1, FGD2, ARF6*AXON GUIDANCE*OPHN1, UBB*LIPID CATABOLIC PROCESS*CPT1A, PLA2G15, SMPD3, ECH1*PHOSPHOLIPID BIOSYNTHETIC PROCESS*ETNK1, PIGO, PIGV, PIK3C2A, AGPAT1, SGMS1, IMPA1*NEGATIVE REGULATION OF NUCLEOBASENUCLEOSIDENUCLEOTIDE AND NUCLEIC ACID METABOLIC PROCESS*CDT1, ZHX1, GMNN, DRAP1, TIPIN, ZMYND11, PA2G4, GTPBP4, PHB, STAT3*CYTOKINESIS*RACGAP1, NUSAP1, PRC1*SPLICEOSOME ASSEMBLY*SCAF11, SF3A2, SRSF1, SRSF5, SF3A1, SNRPD1*GLYCEROPHOSPHOLIPID BIOSYNTHETIC PROCESS*PIGO, PIGV, PIK3C2A, AGPAT1, IMPA1*NUCLEOBASENUCLEOSIDE AND NUCLEOTIDE METABOLIC PROCESS*TYMS, PPAT, ADM, NUDT5, FPGS, NDUFS1*NUCLEAR IMPORT*KPNA2, HNRNPA1, ZFYVE9, RANBP2, PPIH, KPNB1* Table 11Genes and gene sets identified from the classification of p53 deletion versus no deletion (the methods used were ccscore and ccscore.lasso for the individual-gene and gene set analysis, respectively)Disease comparisonAnalysis typeGene setGenesP53 deletion versus no deletionIndividual-gene analysis*ACADVL, ADPRM, ARHGAP19, ASB7, BTBD10, C17orf85, C1QBP, CEP85, CKS2, CRK, CTDNEP1, CTNS, CYB5D1, DHX33, ELK1, ELP5, EZH2, FANCI, FXR2, GABARAP, GEMIN4, GLOD4, GPS2, GTF2E1, HARBI1, HMMR, HPS3, INPP5* *K, ITGAE, KIAA0753, KIF18B, LOC101928000, MAD2L1, MED11, MIS12, MPDU1, NAA38, NXT2, OIP5, P2RX1, PCMTD1, PFAS, PITPNA, PITPNA*-*AS1, PRC1, PRPF8, RABEP1, RANGRF, RBBP8, RNMTL1, SAPCD2, SAT2, SENP3, SHPK, SPAG7, TMEM107, TMEM256, TP53, TPX2, TRAPPC2, UBE2G1, VAMP2, WEE1, ZBTB4, ZNF33B, ZWILCH*Gene set analysis (positional)chr6q13*SENP6, MYO6*chr17p11*MAP2K4, TTC19*chr10q24*ARHGAP19*chr1p34*NSUN4, HYI, KIF2C*chr6q16*MANEA, FBXL4, UBE2J1*chr15q26*PRC1, ASB7*chr3q28*AP2M1, OPA1*chr9q22*CKS2*chr6q23*CITED2, STX7*chr17p13*SAT2, SPAG7, RABEP1, PRPF8, MED11, PFAS, VAMP2, GABARAP, ZBTB4, RNMTL1, CYB5D1, CTNS, DHX33, SENP3, C1QBP, MIS12, TP53, PITPNA, TMEM107, C17orf85, CRK, ACADVL, ITGAE, MPDU1, P2RX1, GPS2, GEMIN4, KIAA0753, PHF23, SLC25A11, NUP88, LOC728392, WDR81, PAFAH1B1, MYBBP1A, DERL2, TSR1* Table 12Number of genes selected and number of overlapping genes in the individual-gene and gene set analysis (the methods used were ccscore and ccscore.lasso for the individual-gene and gene set analysis, respectively)Disease Comparison\# genes selected in individual-gene analysis\# genes selected in gene set analysis\# overlapping genesNormal versus MGUS20964MGUS versus SMM11262SMM versus MM192603*P53* deletion versus no deletion665532

Computing Time {#Sec14}
--------------

We recorded computing time for all the methods in the individual-gene analysis (Table [13](#Tab13){ref-type="table"}). The evaluations were conducted on a laptop using 64-bit Windows 7 and running on a 4-core 3 GHz CPU with 8 GB of memory. For all the methods except Lasso, we started with all 9624 genes. For random forests, however, we included another filtering step to consider only the top 1500 differentially expressed genes prior to model selection. Our experience is that random forests can be very slow without pre-filtering. As shown in Table [13](#Tab13){ref-type="table"}, computing time increases as sample size increases. The ccscore/score/pcscore finished in decent amounts of time (a couple of minutes) but Lasso was no doubt the fastest algorithm in all cases.Table 13Computing time (in minutes) for training different models in individual-gene analysis. Note that there were 9624 genes to begin with for the Lasso, score, ccscore, and pcscore methods, and 1500 genes for random forest (rf)ComparisonSample size in training setLassoscoreccscorepcscorerfNormal versus MGUS980.041.031.051.080.17MGUS versus SMM1620.051.251.241.260.27SMM versus MM2630.081.711.661.690.39*P53* deletion versus no deletion4220.122.252.252.270.61

Conclusions and Discussion {#Sec15}
==========================

In this paper, we evaluated 15 methods for gene set analysis in classification problems using four GEP myeloma datasets and three types of biological gene sets, encompassing a total of 12 scenarios. By comparing the 15 methods with individual-gene methods, we conclude that, overall, the gene set analysis provided more accurate models than the individual-gene analysis. Within a biologically defined gene set, genes are more likely to be co-regulated or co-expressed. We propose to use linear methods such as the ccscore, score, and pcscore (an extension of the SuperPC \[[@CR1]\]) for calculating gene set scores before constructing final predictive models.

Our overall results after averaging across different datasets/gene sets are comparable to those reported by other authors. For example, Ma et al. \[[@CR17]\] proposed using Lasso within gene clusters to first select important genes before applying group Lasso \[[@CR18]\] on the refined gene clusters. In four microarray datasets, they demonstrated either equal or better performance of their method than using regular Lasso in individual-gene analysis. In our study, lasso.lasso, ccscore.lasso, score.lasso, and pcscore.lasso are similar to their approach. Although both are two-step procedures, in their 1st step they created refined gene clusters rather than summary genet set scores. As shown in Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}, when compared to regular Lasso, the ccscore.lasso, score.lasso, and pcscore.lasso each had a reduction in error rate between 0.01 and 0.02, although lasso.lasso had a 0.01 increase in error rate.

Our general approach resembles with that of Chen and Wang \[[@CR16]\]. In the 1st step they created "super gene scores" with SuperPC \[[@CR1]\], and in the 2nd step they employed either Lasso or again SuperPC using the super gene scores as predictors. With two microarray survival datasets they demonstrated the superiority of their methods when compared to not using gene set information. Our pcscore is essentially an extension of the SuperPC for binary outcomes, and therefore our pcscore.pcscore and pcscore. lasso directly correspond to their methods except that they focused on survival prediction instead of classification. When comparing to only using pcscore or lasso in individual-gene analysis, we saw an averaged reduction of at least 0.02 in error rate for pcscore.pcscore and pcscore.lasso (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}), confirming comparability of our results with theirs.

Additionally, Tai and Pan \[[@CR15]\] proposed a modified LDA approach to incorporate pathway information. With both simulated and real datasets, their method was shown to perform better than not incorporatingpathway information (e.g., when compared to PAM \[[@CR35]\], which considers genes as independent). Genes are naturally not independent from each other, therefore the improvements by their method were reasonable and expected. Importantly, our ccscore/score/pcscore methods already draw strength by combining correlated genes. As Park et al. \[[@CR36]\] have shown, averaging genes within gene clusters can improve prediction accuracy. Our score method is essentially an extension of the averaged gene expression method to account for genes with both positive and negative correlations with the outcome. Although it is beyond the scope of this paper, it would be interesting to apply their approach and PAM on myeloma datasets in future research. Further investigations on the genes identified to examine whether the gene set analysis could provide more coherent biological insights into the myeloma disease mechanisms would be another avenue of research.
